Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.
Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L, Gatica H, Schiattino I, Salazaro L, Catalan D, Valenzuela O, Salazar-Onfray F, Aguillón JC. Cuchacovich M, et al. Among authors: soto l. Scand J Rheumatol. 2006 Nov-Dec;35(6):435-40. doi: 10.1080/03009740600904284. Scand J Rheumatol. 2006. PMID: 17343250
The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism.
Soto L, Sabugo F, Catalan D, Wurmann P, Cermenatti T, Gatica H, Aravena O, Salazar L, Aguillón JC, Cuchacovich M. Soto L, et al. Clin Rheumatol. 2011 Mar;30(3):391-5. doi: 10.1007/s10067-011-1679-4. Epub 2011 Jan 14. Clin Rheumatol. 2011. PMID: 21234628
The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis.
Cuenca J, Cuchacovich M, Pérez C, Ferreira L, Aguirre A, Schiattino I, Soto L, Cruzat A, Salazar-Onfray F, Aguillón JC. Cuenca J, et al. Among authors: soto l. Rheumatology (Oxford). 2003 Feb;42(2):308-13. doi: 10.1093/rheumatology/keg092. Rheumatology (Oxford). 2003. PMID: 12595628
Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.
Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Pérez C, Aguirre A, Salazar-Onfray F, Aguillón JC. Cuchacovich M, et al. Among authors: soto l. Scand J Rheumatol. 2004;33(4):228-32. doi: 10.1080/03009740410005863. Scand J Rheumatol. 2004. PMID: 15370717 Clinical Trial.
Systemic vasculitis associated with Fasciola hepatica infection.
Llanos C, Soto L, Sabugo F, Gallegos I, Valenzuela O, Verdaguer J, Cuchacovich M. Llanos C, et al. Among authors: soto l. Scand J Rheumatol. 2006 Mar-Apr;35(2):143-6. doi: 10.1080/03009740500303231. Scand J Rheumatol. 2006. PMID: 16641050
334 results